Technology
Health
Pharmaceutical

Amphastar Pharmaceuticals

$21.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.48 (2.33%) Today
+$0.48 (2.33%) Today

Why Robinhood?

You can buy or sell AMPH and other stocks, options, ETFs, and crypto commission-free!

About

Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. Read More The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Employees
2,078
Headquarters
Rancho Cucamonga, California
Founded
1996
Market Cap
961.07M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
205.51K
High Today
$21.23
Low Today
$20.44
Open Price
$20.62
Volume
126.23K
52 Week High
$25.43
52 Week Low
$14.40

Collections

Technology
Health
Pharmaceutical
2014 IPO
US
North America

News

Seeking AlphaMar 19

FDA approves Amphastar's ANDA for enoxaparin sodium injection

The FDA has approved Amphastar Pharmaceuticals' Abbreviated New Drug Application (“ANDA”) for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) Multiple Dose Vial (MDV). The Company plans to launch Enoxaparin MDV in Q2. According to IQVIA, annual U.S sales for year ended December 31, 2018 for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) MDV was ~$11M....

55
Markets InsiderMar 19

Amphastar Pharmaceuticals Receives FDA Approval for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) Multiple Dose Vial

RANCHO CUCAMONGA, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (FDA) granted approval of its Abbreviated New Drug Application (“ANDA”) for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) Multiple Dose Vial (MDV). The company currently manufactures and distributes Enoxaparin Sodium Injection in prefilled syringe form and this approval of the Multiple Dose Vial allows the company to begin offering the full line...

21
Guru FocusMar 15

Amphastar Pharmaceuticals Inc (AMPH) Files 10-K for the Fiscal Year Ended on December 31, 2018

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company engaged in developing, manufacturing, marketing and selling generic and proprietary injectable & inhalation products.

73

Earnings

-$0.05
$0.01
$0.07
$0.13
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
$0.11 per share
Actual
$0.13 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.